Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study

贝伐单抗 医学 危险系数 内科学 单中心 肿瘤科 胶质母细胞瘤 单变量分析 回顾性队列研究 无进展生存期 多元分析 外科
作者
Yusuke Funakoshi,Nobuhiro Hata,Daisuke Kuga,Ryusuke Hatae,Yuhei Sangatsuda,Yutaka Fujioka,Kosuke Takigawa,Ryosuke Otsuji,Aki Sako,Tsuyoshi Yoshitake,Osamu Togao,Akio Hiwatashi,Toru Iwaki,Masahiro Mizoguchi,Koji Yoshimoto
出处
期刊:World Neurosurgery [Elsevier BV]
卷期号:159: e479-e487 被引量:2
标识
DOI:10.1016/j.wneu.2021.12.075
摘要

Controversies exist regarding the aggressive recurrence of glioblastoma after bevacizumab treatment. We analyzed the clinical impact of bevacizumab approval in Japan by evaluating the clinical course and relapse pattern in patients with glioblastoma.We included 100 patients with IDH-wild-type glioblastoma from September 2006 to February 2018 in our institution. The patients were classified into the pre-bevacizumab (n = 51) and post-bevacizumab (n = 49) groups. Overall, progression-free, deterioration-free, and postprogression survivals were compared. We analyzed the relapse pattern of 72 patients, whose radiographic progressions were evaluated.Significant improvement in progression-free (pre-bevacizumab, 7.5 months; post-bevacizumab, 9.9 months; P = 0.0153) and deterioration-free (pre-bevacizumab, 8.5 months; post-bevacizumab, 13.8 months; P = 0.0046) survivals was seen. These survival prolongations were strongly correlated (r: 0.91, P < 0.0001). The nonenhancing tumor pattern was novel in the post-bevacizumab era (5 of 33). The presence of a nonenhancing tumor did not indicate poor postprogression survival (hazard ratio: 0.82 [0.26-2.62], P = 0.7377). The rate of early focal recurrence was significantly lower (P = 0.0155) in the post-bevacizumab (4 of 33) than in the pre-bevacizumab (18 of 39) era. There was a significant decrease in early focal recurrence after approval of bevacizumab in patients with unresectable tumors (P = 0.0110). The treatment era was significantly correlated with a decreased rate of early focal recurrence (P = 0.0021, univariate analysis; P = 0.0144, multivariate analysis).Approval of first-line bevacizumab in Japan for unresectable tumors may prevent early progression and clinical deterioration of glioblastoma without worsening the clinical course after relapse.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
完美世界应助mariawang采纳,获得10
刚刚
刚刚
遐蝶发布了新的文献求助10
刚刚
wangjing11完成签到,获得积分10
1秒前
轻松小张发布了新的文献求助900
1秒前
机智采枫完成签到 ,获得积分10
1秒前
脑洞疼应助云栖采纳,获得10
1秒前
峥2发布了新的文献求助10
2秒前
2秒前
3秒前
3秒前
4秒前
4秒前
5秒前
5秒前
lm发布了新的文献求助10
6秒前
6秒前
6秒前
zhao完成签到,获得积分10
6秒前
weiwei完成签到,获得积分10
6秒前
科研通AI2S应助姜凯采纳,获得10
7秒前
孙福禄应助西西采纳,获得10
8秒前
孙福禄应助西西采纳,获得10
8秒前
8秒前
单纯青槐发布了新的文献求助10
8秒前
8秒前
8秒前
luckbaby完成签到,获得积分10
9秒前
方赫然发布了新的文献求助10
9秒前
JerryZ发布了新的文献求助10
9秒前
今后应助高贵绿真采纳,获得10
9秒前
Ava应助mariawang采纳,获得10
9秒前
9秒前
菜不透发布了新的文献求助10
10秒前
10秒前
纸猫发布了新的文献求助10
10秒前
11秒前
weiwei发布了新的文献求助10
11秒前
poli发布了新的文献求助10
12秒前
诚心尔琴发布了新的文献求助10
13秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988786
求助须知:如何正确求助?哪些是违规求助? 3531116
关于积分的说明 11252493
捐赠科研通 3269766
什么是DOI,文献DOI怎么找? 1804771
邀请新用户注册赠送积分活动 881870
科研通“疑难数据库(出版商)”最低求助积分说明 809021